Literature DB >> 17470539

Inhibition of dendritic cell maturation by malaria is dose dependent and does not require Plasmodium falciparum erythrocyte membrane protein 1.

Salenna R Elliott1, Timothy P Spurck, Joelle M Dodin, Alexander G Maier, Till S Voss, Francisca Yosaatmadja, Paul D Payne, Geoffrey I McFadden, Alan F Cowman, Stephen J Rogerson, Louis Schofield, Graham V Brown.   

Abstract

Red blood cells infected with Plasmodium falciparum (iRBCs) have been shown to modulate maturation of human monocyte-derived dendritic cells (DCs), interfering with their ability to activate T cells. Interaction between Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) and CD36 expressed by DCs is the proposed mechanism, but we show here that DC modulation does not require CD36 binding, PfEMP1, or contact between DCs and infected RBCs and depends on the iRBC dose. iRBCs expressing a PfEMP1 variant that binds chondroitin sulfate A (CSA) but not CD36 were phagocytosed, inhibited lipopolysaccharide (LPS)-induced phenotypic maturation and cytokine secretion, and abrogated the ability of DCs to stimulate allogeneic T-cell proliferation. CD36- and CSA-binding iRBCs showed comparable inhibition. P. falciparum lines rendered deficient in PfEMP1 expression by targeted gene knockout or knockdown also inhibited LPS-induced phenotypic maturation, and separation of DCs and iRBCs in transwells showed that inhibition was not contact dependent. Inhibition was observed at an iRBC:DC ratio of 100:1 but not at a ratio of 10:1. High doses of iRBCs were associated with apoptosis of DCs, which was not activation induced. Lower doses of iRBCs stimulated DC maturation sufficient to activate autologous T-cell proliferation. In conclusion, modulation of DC maturation by P. falciparum is dose dependent and does not require interaction between PfEMP1 and CD36. Inhibition and apoptosis of DCs by high-dose iRBCs may or may not be physiological. However, our observation that low-dose iRBCs initiate functional DC maturation warrants reevaluation and further investigation of DC interactions with blood-stage P. falciparum.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17470539      PMCID: PMC1932960          DOI: 10.1128/IAI.00095-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  57 in total

1.  Paralysis of dendritic cell IL-12 production by microbial products prevents infection-induced immunopathology.

Authors:  C Reis e Sousa; G Yap; O Schulz; N Rogers; M Schito; J Aliberti; S Hieny; A Sher
Journal:  Immunity       Date:  1999-11       Impact factor: 31.745

2.  Purification of mature-stage Plasmodium falciparum by gelatine flotation.

Authors:  I D Goodyer; J Johnson; R Eisenthal; D J Hayes
Journal:  Ann Trop Med Parasitol       Date:  1994-04

3.  A routine flat embedding method for electron microscopy of microorganisms allowing selection and precisely orientated sectioning of single cells by light microscopy.

Authors:  O L Reymond; J D Pickett-Heaps
Journal:  J Microsc       Date:  1983-04       Impact factor: 1.758

4.  Cellular changes and apoptosis in the spleens and peripheral blood of mice infected with blood-stage Plasmodium chabaudi chabaudi AS.

Authors:  H Helmby; G Jönsson; M Troye-Blomberg
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

5.  Identification of a Plasmodium falciparum intercellular adhesion molecule-1 binding domain: a parasite adhesion trait implicated in cerebral malaria.

Authors:  J D Smith; A G Craig; N Kriek; D Hudson-Taylor; S Kyes; T Fagan; T Fagen; R Pinches; D I Baruch; C I Newbold; L H Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

6.  Adherence of infected erythrocytes to venular endothelium selects for antigenic variants of Plasmodium falciparum.

Authors:  B A Biggs; R F Anders; H E Dillon; K M Davern; M Martin; C Petersen; G V Brown
Journal:  J Immunol       Date:  1992-09-15       Impact factor: 5.422

7.  Multiple ligands for cytoadherence can be present simultaneously on the surface of Plasmodium falciparum-infected erythrocytes.

Authors:  S C Chaiyaroj; R L Coppel; S Novakovic; G V Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

Review 8.  Suppression of adaptive immunity to heterologous antigens during Plasmodium infection through hemozoin-induced failure of dendritic cell function.

Authors:  Owain R Millington; Caterina Di Lorenzo; R Stephen Phillips; Paul Garside; James M Brewer
Journal:  J Biol       Date:  2006-04-12

9.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.

Authors:  F Sallusto; A Lanzavecchia
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

10.  Chondroitin sulfate A is a cell surface receptor for Plasmodium falciparum-infected erythrocytes.

Authors:  S J Rogerson; S C Chaiyaroj; K Ng; J C Reeder; G V Brown
Journal:  J Exp Med       Date:  1995-07-01       Impact factor: 14.307

View more
  43 in total

Review 1.  Approaches to malaria vaccine development using the retrospectroscope.

Authors:  Vanessa Sardá; David C Kaslow; Kim C Williamson
Journal:  Infect Immun       Date:  2009-05-18       Impact factor: 3.441

2.  From secretome analysis to immunology: chitosan induces major alterations in the activation of dendritic cells via a TLR4-dependent mechanism.

Authors:  Christian Villiers; Mireille Chevallet; Hélène Diemer; Rachel Couderc; Heidi Freitas; Alain Van Dorsselaer; Patrice N Marche; Thierry Rabilloud
Journal:  Mol Cell Proteomics       Date:  2009-03-11       Impact factor: 5.911

3.  Profoundly Reduced CD1c+ Myeloid Dendritic Cell HLA-DR and CD86 Expression and Increased Tumor Necrosis Factor Production in Experimental Human Blood-Stage Malaria Infection.

Authors:  Jessica R Loughland; Gabriela Minigo; Julie Burel; Peta E Tipping; Kim A Piera; Fiona H Amante; Christian R Engwerda; Michael F Good; Denise L Doolan; Nicholas M Anstey; James S McCarthy; Tonia Woodberry
Journal:  Infect Immun       Date:  2016-04-22       Impact factor: 3.441

Review 4.  Modulation of dendritic cell responses by parasites: a common strategy to survive.

Authors:  César A Terrazas; Luis I Terrazas; Lorena Gómez-García
Journal:  J Biomed Biotechnol       Date:  2010-02-24

5.  Modulation of the immune and inflammatory responses by Plasmodium falciparum schizont extracts: role of myeloid dendritic cells in effector and regulatory functions of CD4+ lymphocytes.

Authors:  Ann Maria Clemente; Giulia Fadigati; Roberto Caporale; Damiano G Marchese; Giuseppe Castronovo; Anna Rosa Sannella; Carlo Severini; Federica Verra; Enrico Garaci; Federico Cozzolino; Maria Gabriella Torcia
Journal:  Infect Immun       Date:  2013-03-18       Impact factor: 3.441

Review 6.  Effects of type I interferons in malaria.

Authors:  Ismail Sebina; Ashraful Haque
Journal:  Immunology       Date:  2018-07-05       Impact factor: 7.397

7.  Dual effect of Plasmodium-infected erythrocytes on dendritic cell maturation.

Authors:  Esther Bettiol; Daniel Carapau; Cristina Galan-Rodriguez; Carlos Ocaña-Morgner; Ana Rodriguez
Journal:  Malar J       Date:  2010-03-01       Impact factor: 2.979

8.  A Plasmodium yoelii soluble factor inhibits the phenotypic maturation of dendritic cells.

Authors:  Jamie M Orengo; Kurt A Wong; Carlos Ocaña-Morgner; Ana Rodriguez
Journal:  Malar J       Date:  2008-12-15       Impact factor: 2.979

9.  Plasmodium falciparum exposure in utero, maternal age and parity influence the innate activation of foetal antigen presenting cells.

Authors:  Nadine Fievet; Stefania Varani; Samad Ibitokou; Valérie Briand; Stéphanie Louis; René Xavier Perrin; Achille Massougbogji; Anne Hosmalin; Marita Troye-Blomberg; Philippe Deloron
Journal:  Malar J       Date:  2009-11-05       Impact factor: 2.979

Review 10.  Adhesion of Plasmodium falciparum-infected erythrocytes to human cells: molecular mechanisms and therapeutic implications.

Authors:  J Alexandra Rowe; Antoine Claessens; Ruth A Corrigan; Mònica Arman
Journal:  Expert Rev Mol Med       Date:  2009-05-26       Impact factor: 5.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.